Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $37.75 (market cap $29.19M), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 172× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 64 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QDTY | TVTX | |
|---|---|---|
Market Cap | $29.19M | $5.02B |
Volume | 17,129 | 2,060,842 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $67.52 |
52-Week Low | $36.57 | $26.79 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $38.94, down 0.36% with bearish technical signals from moving averages. The ETF maintains a consistent weekly dividend distribution strategy, with recent payments ranging from $0.19 to $0.30 per share. Technical indicators show mixed signals with RSI in neutral territory while ADX suggests weakening trend strength. The stock faces resistance at $40 with support clustered around $39.
The outlook remains cautious given bearish technical momentum and concentrated support levels. Dividend consistency provides income appeal, but technical weakness and tight trading range near current levels suggest limited near-term upside potential. Key risks include market volatility impact on covered call strategies and dependency on Nasdaq 100 performance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
